Publication:

Semaglutide salt versus base formulations: a regulatory and pharmacovigilance imperative

Obesity is one of the most dreaded epidemics in the world, and it is a significant challenge to global public health that must be addressed aggressively through clinical and pharmacological interventions. The unprecedented rise in the global use of glucagon-like peptide-1 receptor agonists for the treatment of obesity and type 2 diabetes has created a critical regulatory and pharmacological challenge related to the proliferation of mass-marketed compounded alternatives.